RPG Life Sciences
Market Cap
₹4.8b
Last Updated
2019/12/13 12:56 UTC
Data Sources
Company Financials
Executive Summary
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic dosage forms, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with solid track record.
Share Price & News
How has RPG Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RPGLIFE's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.7%
RPGLIFE
-0.5%
IN Pharmaceuticals
-1.1%
IN Market
1 Year Return
18.7%
RPGLIFE
-4.9%
IN Pharmaceuticals
2.9%
IN Market
Return vs Industry: RPGLIFE exceeded the Indian Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: RPGLIFE exceeded the Indian Market which returned 2.9% over the past year.
Shareholder returns
| RPGLIFE | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.7% | -0.5% | -1.1% |
| 30 Day | 5.1% | 2.3% | -0.8% |
| 90 Day | 50.6% | 2.8% | 6.0% |
| 1 Year | 20.1%18.7% | -4.0%-4.9% | 4.9%2.9% |
| 3 Year | -36.2%-37.9% | -13.4%-15.2% | 32.7%25.7% |
| 5 Year | 249.9%236.9% | -7.6%-10.4% | 41.2%28.5% |
Price Volatility Vs. Market
How volatile is RPG Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Does RPG Life Sciences Limited (NSE:RPGLIFE) Fare As A Dividend Stock?1 month ago | Simply Wall St
Introducing RPG Life Sciences (NSE:RPGLIFE), The Stock That Slid 61% In The Last Three Years2 months ago | Simply Wall St
A Note On RPG Life Sciences Limited's (NSE:RPGLIFE) ROE and Debt To EquityValuation
Is RPG Life Sciences undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RPGLIFE (₹291.1) is trading below our estimate of fair value (₹3398.99)
Significantly Below Fair Value: RPGLIFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RPGLIFE is poor value based on its PE Ratio (19.4x) compared to the Pharmaceuticals industry average (15.2x).
PE vs Market: RPGLIFE is poor value based on its PE Ratio (19.4x) compared to the Indian market (12.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RPGLIFE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RPGLIFE is overvalued based on its PB Ratio (2.8x) compared to the IN Pharmaceuticals industry average (1.4x).
Next Steps
Future Growth
How is RPG Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
12.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RPG Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Check out RPG Life Sciences's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- RPG Life Sciences competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has RPG Life Sciences performed over the past 5 years?
25.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RPGLIFE has high quality earnings.
Growing Profit Margin: RPGLIFE's current net profit margins (7.1%) are higher than last year (3.1%).
Past Earnings Growth Analysis
Earnings Trend: RPGLIFE has become profitable over the past 5 years, growing earnings by 25.9% per year.
Accelerating Growth: RPGLIFE's earnings growth over the past year (133.1%) exceeds its 5-year average (25.9% per year).
Earnings vs Industry: RPGLIFE earnings growth over the past year (133.1%) exceeded the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: RPGLIFE's Return on Equity (14.4%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is RPG Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: RPGLIFE's short term assets (₹1.2B) exceed its short term liabilities (₹824.4M).
Long Term Liabilities: RPGLIFE's short term assets (₹1.2B) exceed its long term liabilities (₹99.4M).
Debt to Equity History and Analysis
Debt Level: RPGLIFE's debt to equity ratio (5%) is considered satisfactory.
Reducing Debt: RPGLIFE's debt to equity ratio has reduced from 26.5% to 5% over the past 5 years.
Debt Coverage: RPGLIFE's debt is well covered by operating cash flow (780.6%).
Interest Coverage: RPGLIFE's interest payments on its debt are well covered by EBIT (12.2x coverage).
Balance Sheet
Inventory Level: RPGLIFE has a high level of physical assets or inventory.
Debt Coverage by Assets: RPGLIFE's debt is covered by short term assets (assets are 13.4x debt).
Next Steps
Dividend
What is RPG Life Sciences's current dividend yield, its reliability and sustainability?
0.82%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: RPGLIFE's dividend (0.82%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).
High Dividend: RPGLIFE's dividend (0.82%) is low compared to the top 25% of dividend payers in the Indian market (2.55%).
Stability and Growth of Payments
Stable Dividend: RPGLIFE's dividend payments have been volatile in the past 10 years.
Growing Dividend: RPGLIFE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (15.9%), RPGLIFE's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of RPG Life Sciences's salary, the management and board of directors tenure and is there insider trading?
3.0yrs
Average management tenure
CEO
Yugal Kishor Sikri (62yo)
1.2yrs
Tenure
₹22,075,328
Compensation
Mr. Yugal Kishor Choturam Sikri has been Managing Director and Additional Director at RPG Life Sciences Limited since October 1, 2018 .He served as an Independent & Non-Executive Director at RPG Life Scien ...
CEO Compensation Analysis
Compensation vs Market: Yugal Kishor's total compensation ($USD311.99K) is above average for companies of similar size in the Indian market ($USD50.88K).
Compensation vs Earnings: Yugal Kishor's compensation has increased by more than 20% in the past year.
Management Age and Tenure
3.0yrs
Average Tenure
Experienced Management: RPGLIFE's management team is considered experienced (3 years average tenure).
Board Age and Tenure
5.4yrs
Average Tenure
62yo
Average Age
Experienced Board: RPGLIFE's board of directors are considered experienced (5.4 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 6,800 |
| Max Price | ₹255.88 |
| Entity | Company |
| Shares | 6,258 |
| Max Price | ₹255.82 |
| Entity | Company |
| Shares | 15,321 |
| Max Price | ₹255.43 |
| Entity | Company |
| Shares | 9,058 |
| Max Price | ₹257.79 |
| Entity | Company |
| Shares | 3,971 |
| Max Price | ₹254.83 |
| Entity | Company |
| Shares | 16,340 |
| Max Price | ₹255.87 |
| Entity | Company |
| Shares | 3,010 |
| Max Price | ₹255.39 |
| Entity | Company |
| Shares | 5,480 |
| Max Price | ₹254.67 |
| Entity | Company |
| Shares | 12,214 |
| Max Price | ₹255.54 |
| Entity | Company |
| Shares | 4,028 |
| Max Price | ₹255.85 |
| Entity | Company |
| Shares | 2,006 |
| Max Price | ₹255.91 |
| Entity | Company |
| Shares | 4,231 |
| Max Price | ₹256.03 |
| Entity | Company |
| Shares | 4,546 |
| Max Price | ₹242.44 |
| Entity | Company |
| Shares | 970 |
| Max Price | ₹240.44 |
| Entity | Company |
| Shares | 7,582 |
| Max Price | ₹242.59 |
| Entity | Company |
| Shares | 6,379 |
| Max Price | ₹235.91 |
| Entity | Company |
| Shares | 5,844 |
| Max Price | ₹236.48 |
| Entity | Company |
| Shares | 5,307 |
| Max Price | ₹234.70 |
| Entity | Company |
| Shares | 4,000 |
| Max Price | ₹225.09 |
| Entity | Company |
| Shares | 6,163 |
| Max Price | ₹229.99 |
| Entity | Company |
| Shares | 24,694 |
| Max Price | ₹230.85 |
| Entity | Company |
| Shares | 14,128 |
| Max Price | ₹230.82 |
| Entity | Company |
| Shares | 6,246 |
| Max Price | ₹252.47 |
| Entity | Company |
| Shares | 9,736 |
| Max Price | ₹251.10 |
| Entity | Company |
| Shares | 10,446 |
| Max Price | ₹250.87 |
| Entity | Company |
| Shares | 15,675 |
| Max Price | ₹250.87 |
| Entity | Company |
| Shares | 4,923 |
| Max Price | ₹235.78 |
| Entity | Company |
| Shares | 6,886 |
| Max Price | ₹225.79 |
| Entity | Company |
| Shares | 10,964 |
| Max Price | ₹211.65 |
| Entity | Company |
| Shares | 24,610 |
| Max Price | ₹212.25 |
| Entity | Company |
| Shares | 24,657 |
| Max Price | ₹212.75 |
| Entity | Company |
| Shares | 5,159 |
| Max Price | ₹214.88 |
| Entity | Company |
| Shares | 19,783 |
| Max Price | ₹251.37 |
| Entity | Company |
| Shares | 9,750 |
| Max Price | ₹250.77 |
| Entity | Company |
| Shares | 6,571 |
| Max Price | ₹246.07 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
B. Sundaram (52yo)
Business Head of API - International & Specialty
- Tenure: 4.3yrs
Rajesh Shirambekar
Head of Legal
- Tenure: 8.1yrs
Yugal Kishor Sikri (62yo)
MD & Additional Director
- Tenure: 1.2yrs
- Compensation: ₹22.08m
Suchitra Tiwari
Head of Regulatory & Project Management
- Tenure: 0yrs
Mahesh Narayanaswamy
Vice President of Finance
- Tenure: 3.4yrs
Tushar Joshi
Head of Human Resources
- Tenure: 3.3yrs
Himmat Patel
Head of Domestic Manufacturing & Sourcing
- Tenure: 2.7yrs
Kartick Patra
Head of API Operations & Procurement
- Tenure: 2.7yrs
Rajesh Chopra
Site Head - F2
- Tenure: 0yrs
Milind Gujar
Chief Quality Officer
- Tenure: 0.9yrs
Board Members
Lalit Kanodia (78yo)
Independent & Non-Executive Director
- Tenure: 11.8yrs
- Compensation: ₹615.00k
Harsh Goenka (62yo)
Chairman of the Board
- Tenure: 0yrs
- Compensation: ₹600.00k
Manojkumar Maheshwari (53yo)
Independent & Non-Executive Director
- Tenure: 15.4yrs
- Compensation: ₹600.00k
Mahesh Gupta (63yo)
Independent & Non-Executive Director
- Tenure: 16.2yrs
- Compensation: ₹704.00k
Narendra Ambwani (71yo)
Independent & Non-Executive Director
- Tenure: 5.4yrs
- Compensation: ₹664.00k
Yugal Kishor Sikri (62yo)
MD & Additional Director
- Tenure: 1.2yrs
- Compensation: ₹22.08m
Sachin Nandgaonkar (50yo)
Non-Executive Director
- Tenure: 4.9yrs
- Compensation: ₹815.00k
Zahabiya Khorakiwala
Independent & Non-Executive Director
- Tenure: 4.2yrs
- Compensation: ₹410.00k
Company Information
RPG Life Sciences Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: RPG Life Sciences Limited
- Ticker: RPGLIFE
- Exchange: NSEI
- Founded: 1968
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹4.826b
- Shares outstanding: 16.54m
- Website: https://www.rpglifesciences.com
Number of Employees
Location
- RPG Life Sciences Limited
- RPG HOUSE
- 4th Floor
- Mumbai
- Maharashtra
- 400030
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 532983 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Jun 2008 |
| RPGLIFE | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Jun 2008 |
Biography
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic dosage forms, and synthetic active pharmaceutical ingredients (APIs) in In ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/13 12:56 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.